California is experiencing a pharmaceutical renaissance, with Amgen investing $600 million in a new innovation center to drive discovery pipelines and reinforce the U.S. as a leader in next-gen therapeutics. Gilead Sciences is also breaking ground on a Technical Development Hub to accelerate biopharma innovation. These investments underscore the importance of specialized infrastructure in staying competitive. The state’s advanced facilities are ideal for testing and scaling logistics solutions, emphasizing the value of local production in an era of geopolitical unpredictability. This marks a shift towards an integrated pharmaceutical supply chain ecosystem, blending science and logistics to build a smarter foundation for future medicines.

Read more at Yahoo Finance: Why California’s biopharma boom is critical for logistics